Ask AI
MBC Care

CE / CME

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: October 15, 2025

Expiration: April 14, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 57-yr-old postmenopausal woman with a history of high-risk node-positive ER+/HER2- early breast cancer in 2021 and on adjuvant letrozole presents now with gradual fatigue and weight loss. Imaging is notable for findings consistent with MBC, with lesions in bone, mediastinal lymph nodes, and 2 liver lesions. Biopsy confirms ER+/PgR+/HER2 1+ MBC and a ctDNA evaluation shows an activating ESR1 mutation and an activating PIK3CA mutation. Her previous relevant medical history included breast surgery/SLNB followed by adjuvant chemotherapy and radiation therapy. She started adjuvant abemaciclib along with letrozole but discontinued the abemaciclib after 6 months due to poor appetite and diarrhea despite 2 dose reductions.

Which first-line systemic therapy would you recommend for this patient?